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BALB/c mice immunized intraperitoneally (i.p.) and intravenously (i.v.) with Leishmania donovani promas-
tigote membrane antigens (LAg), either free or encapsulated in liposomes, were protected against challenge
infection with L. donovani, whereas mice immunized by the subcutaneous (s.c.) and intramuscular routes were
not protected. Protected mice showed strong parasite resistance in both the liver and spleen, along with
enhanced immunoglobulin G2a and delayed-type hypersensitivity responses. Again, mice vaccinated through
the i.p. and i.v. routes showed high levels of NO production after challenge infection. s.c. vaccination resulted
in an increased capacity of the spleen cells to produce prechallenge transforming growth factor  (TGF-)
levels during the in vitro antigen recall response, whereas i.p. immunization induced production of prechal-
lenge gamma interferon, interleukin-12 (IL-12), and IL-4 levels, with a Th1 bias. Exposure to antigen-
stimulated splenocyte supernatants of i.p. but not s.c. immunized mice activated macrophages for in vitro
parasite killing. As an enhanced level of TGF- was detected in supernatants from unprotected s.c. immunized
mice, neutralization by anti-TGF- antibody enhanced in vitro macrophage killing activity. The suppressive
role of this cytokine was evaluated in vivo by vaccination with liposomal LAg and anti-TGF- antibody. Upon
parasite challenge, these animals showed significant protection in both the liver and spleen. Moreover, the
addition of recombinant TGF- in splenocyte supernatants of i.p. immunized mice in vitro as well as in vivo
inhibited the protective ability of the macrophages by the i.p. route. Thus, the induction of high prechallenge
TGF- limits the efficacy of vaccination by routes that are nonprotective.
Leishmaniasis is a group of vector-borne diseases caused by
obligate intracellular protozoa belonging to the genus Leish-
mania. Clinical manifestations range from self-limiting cutane-
ous leishmaniasis to visceral leishmaniasis (VL), which is a
fatal infection if it is left untreated. With an estimated 350
million people at risk for acquiring infection with Leishmania
parasites, the worldwide prevalence is estimated at approxi-
mately 12 million cases, with 1.5 million new reports of cuta-
neous leishmaniasis and 500,000 new reports of VL each year.
The World Health Organization considers leishmaniasis to be
one of the most serious, epidemic-prone parasitic infectious
diseases occurring sporadically in poor, rural farming areas
(11).
Because of the lack of effective and low-cost treatments and
the irreversibility of tissue damage during infection, consider-
able effort has been devoted to vaccine development. Much
recent research on vaccine development against leishmaniasis
has been directed toward determining strategies that specifi-
cally stimulate protective immune responses in the absence of
those that may cause pathology and/or interfere with protec-
tion (16). Protective immunity against Leishmania is largely
attributed to an IL-12-driven Th1 response and gamma inter-
feron (IFN-) production. Although a disease-promoting role
for IL-4 and the Th2 response in VL is more difficult to iden-
tify, a role for IL-10 and transforming growth factor  (TGF-)
has been documented during murine infection (20). Elevated
levels of IL-10 have also been reported in clinical studies of VL
(30). TGF- has potent immunosuppressive properties, en-
hances disease progression, and may be instrumental in pre-
vention of cure of leishmaniasis (39). IL-10 can be produced by
many cell types, including B cells, macrophages, dendritic cells
(DCs), and Th2 cells. Recently, a population of Th1 cells was
found to be a source of IL-10 in Leishmania infection (27).
Macrophages, fibroblasts, and inflammatory cells, such as neu-
trophils and eosinophils, are sources of TGF-. Moreover,
distinct populations of regulatory T cells (Treg cells) can be the
source of IL-10 and TGF-. Natural Treg cells produce both
IL-10 and TGF-. Inducible regulatory T-cell populations in-
clude T regulatory 1 (Tr1) cells, which secrete high levels of
IL-10 with or without TGF-, whereas T helper 3 (Th3) reg-
ulatory T cells express high levels of TGF- (5).
Extensive vaccine studies against Leishmania with animal
models have been carried out using strategies ranging from live
parasites to nonliving protein- or DNA-based vaccines (16).
The success of these vaccines depends upon the expression of
immunity favorable for resistance against challenge infection.
Of the many variables in vaccination, a major factor is the
route of immunization. Vaccination with live parasites by dif-
ferent routes has shown that the subcutaneous (s.c.) route
influences cell types recruited to the secondary site of infection
and clears parasites more efficiently than the intradermal route
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(33). The intramuscular (i.m.) route has been the route of
choice for DNA vaccination. However, optimization of this
vaccine for generation of long-lasting protection revealed that
intradermal immunization was more efficient, requiring five-
fold less vaccine than both the i.m. and s.c. routes (22). For
leishmanial protein antigens, including single proteins, differ-
ent routes, such as the intraperitoneal (i.p.), intravenous (i.v.),
and s.c. routes, have been used for generation of protective
immunity (14, 17, 31). While it is agreed that the route of
immunization of protein antigens may also influence the
development of an immune response, the effects of various
routes on the level and type of immune response generated
and their subsequent impact on challenge infection have
remained largely unknown.
We previously examined the ability of membrane antigens of
Leishmania donovani promastigotes (LAg) to induce protec-
tive immunity in BALB/c mice. We reported that when the i.p.
route of immunization was used, LAg entrapped in positively
charged liposomes induced significant levels of protection (1).
In the present study, we compared the protective efficacies of
LAg, alone or entrapped in these liposomes and administered
by four different routes, namely, the i.p., i.v., s.c., and i.m.
routes, in BALB/c mice against L. donovani infection to un-
derstand the immunological correlates of protective and non-
protective routes. In addition, we investigated the mechanisms
underlying the failure of vaccination by the nonprotective
routes.
MATERIALS AND METHODS
Animals and parasites. BALB/c mice, bred in the Indian Institute of Chemical
Biology’s animal facility (Kolkata, India), were 4 to 6 weeks old at the onset of
the experiments. Mice were handled in accordance with institutional guidelines
and used with relevant committee approval. L. donovani strain AG83 (MHOM/
IN/1983/AG83) promastigotes were grown at 22°C in medium 199 supplemented
with penicillin G sodium (100 U/ml), streptomycin sulfate (100 g/ml), and 10%
heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO) and
subcultured in the same medium at an average density of 2  106 cells/ml (1).
Preparation of LAg. LAg were prepared from L. donovani promastigotes as
described earlier (1). Briefly, stationary-phase promastigotes were washed in
phosphate-buffered saline (PBS), pH 7.2, and were resuspended in 5 mM Tris-
HCl buffer, pH 7.6. The suspension was vortexed and centrifuged at 2,310 g for
10 min. The crude ghost membrane pellet was resuspended in the same buffer
and sonicated for 3 min by an ultrasound probe sonicator (Misonix, Farmingdale,
NY). The suspension was centrifuged at 5,910  g for 30 min, and the superna-
tant containing the LAg was stored at 70°C until use. The amount of protein
obtained from a 1.0-g cell pellet was approximately 14 mg (18).
Entrapment of antigens in liposomes. Liposomes were prepared with egg
lecithin (27 mol), cholesterol (Sigma-Aldrich), and stearylamine (Fluka, Buchs
SG) at a molar ratio of 7:2:2 as described previously (1). Empty and LAg-
containing liposomes were prepared by the dispersion of lipid film in 1 ml PBS
alone or containing 1 mg/ml LAg. The amount of associated LAg per milligram
of egg lecithin was 36 g.
Vaccination and challenge infection. For vaccination, mice received three
doses of 20 g of LAg, either in PBS or incorporated into liposomes, by four
different routes, i.e., the i.p., i.v., s.c., and i.m. routes, in a total volume of 200 l
at 2-week intervals. Alternatively, animals received three s.c. vaccinations of LAg
entrapped in liposomes together with 100 g of either anti-TGF- (clone 9016.2;
R&D Systems, Minneapolis, MN) or control isotype antibody (mouse immuno-
globulin G1 [IgG1]; R&D Systems). Again, mice were injected i.p. with three
doses of LAg entrapped in liposomes alone or in combination with 5 g of
recombinant TGF- (rTGF-; R&D Systems) at 2-week intervals. Control mice
received nothing, empty liposomes, or anti-TGF- antibody through the respec-
tive routes. Ten days after the last booster, groups of mice were either sacrificed
for immunological assays or infected i.v. with 2.5  107 freshly transformed
stationary-phase promastigotes in 200 l PBS.
Evaluation of infection. After 2 and 4 months of challenge infection, the
course of infection was monitored by the microscopic examination of Giemsa-
stained impression smears of liver and spleen. The parasite load was expressed
in Leishman Donovan units, calculated by the following formula: number of
amastigotes per 1,000 cell nuclei  organ weight (milligram) (32).
Antibody responses. Sera from immunized and infected animals were analyzed
by enzyme-linked immunosorbent assay (ELISA) for the presence of LAg-spe-
cific antibodies. In brief, 96-well microtiter plates (Nunc, Naperville, IL) were
coated with LAg (25 g/ml) and blocked to prevent nonspecific binding. The
plates were then incubated with sera at a 1:1,000 dilution, followed by horserad-
ish peroxidase-conjugated goat anti-mouse IgG (1:5,000) (Sigma-Aldrich), IgG1,
and IgG2a (1:1,000) (BD Pharmingen, San Diego, CA). The color reaction was
developed, and the absorbance was read in an ELISA plate reader (Thermo,
Waltham, MA) at 450 nm (1).
DTH. After the last vaccination, 2 and 4 months after challenge infection,
delayed-type hypersensitivity (DTH) was determined as an index of cell-medi-
ated immunity. The response was evaluated by measuring the difference in
footpad swelling 24 h following intradermal inoculation of the test footpad with
50 l of LAg (800 g/ml) and the swelling of the control (PBS-injected) footpad
with a constant-pressure caliper (Starrett Company, Athol, MA) (1).
Cytokine assays. Single-cell suspensions were prepared from spleens of im-
munized, infected (for 2 and 4 months) mice and cultured in RPMI 1640 sup-
plemented with 10% FBS, penicillin G sodium (100 U/ml), streptomycin sulfate
(100 g/ml), and 50 M -mercaptoethanol (Sigma-Aldrich) in triplicate in a
96-well flat-bottomed plate (Nunc) at a density of 2  105 cells/well in a final
volume of 200 l. Cells were stimulated with LAg (10 g/ml) for 72 h, and
supernatants were collected. IFN-, IL-12, IL-4, IL-10, tumor necrosis factor
alpha (TNF-) (BD Pharmingen), and TGF- (R&D Systems) levels were mea-
sured in supernatants by ELISA following the manufacturers’ instructions (19).
For TGF-, supernatants were acidified prior to the assay.
Determination of NO concentration. NO, quantified by the accumulation of
nitrite in the supernatants, was measured according to the method of Ding et al.
(12). Briefly, samples were mixed with an equal volume of Griess reagent [1%
sulfanilamide and 0.1% N-(1-napthyl)-ethylenediamine dihydrochloride in 2.5%
H3PO4] and incubated at room temperature for 10 min. Absorbance was then
measured at 540 nm. Sodium nitrite was used as a standard (19).
In vitro growth of L. donovani in macrophages. Macrophages were collected by
peritoneal lavage from naïve mice and cultured on glass coverslips (18 mm2; 106
macrophages/coverslip) in 0.5 ml of RPMI 1640 with 10% FBS (3). Macrophages
from naïve mice were pretreated for 12 to 18 h with spleen cell supernatants from
immunized mice alone or in combination with rTGF- (R&D Systems) at 0.5 to
100 ng/ml. rIFN- (R&D Systems) at 10 ng/ml was used as a positive control. For
neutralization of cytokines, macrophages were pretreated with anti-IL-10 anti-
body, anti-IL-4 antibody (BD Pharmingen), and anti-TGF- antibody (R&D
Systems) at 10 g/ml. Appropriate isotype-matched antibodies were used as
controls. Macrophages were infected with promastigotes at a ratio of 10 para-
sites/macrophage. After 3 h of incubation, unphagocytosed parasites were re-
moved by washing with PBS and cultured in the same medium with supernatants,
rIFN-, antibodies, or rTGF- at similar concentrations for 72 h. Cells fixed in
methanol were stained with Giemsa stain for determination of intracellular
parasite numbers. Results are shown as amastigote numbers per 100 macro-
phages, and at least 200 macrophages were counted per coverslip.
Statistical analysis. All data were analyzed by one-way analysis of variance,
using Graph Pad Prism, version 4.0 (Graph Pad Software, San Diego, CA).
Results with P values of 0.05 were considered statistically significant.
RESULTS
Immunization by i.p. and i.v. routes, but not s.c. and i.m.
routes, induces protection against L. donovani infection in
BALB/c mice. The outcomes of challenge infections in BALB/c
mice following vaccination via four different routes with LAg
and LAg in liposomes were evaluated. In contrast to self-
limiting infection (26, 29), inoculation of BALB/c mice with L.
donovani strain AG83 leads to progressive infection in the liver
and spleen, corresponding with hepato- and splenomegaly (2,
7, 19, 24). Figure 1A shows that mice vaccinated with LAg
through the i.p. route demonstrated partial reductions in liver
parasite load at 2 (38%; P  0.01) and 4 (48%; P  0.001)
months of infection compared to controls. Higher levels of
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FIG. 1. Clinical outcomes following L. donovani challenge in BALB/c mice immunized via four different routes. Mice were immunized three times
with 20 g of LAg, alone or entrapped in liposomes, at 2-week intervals through the i.p., i.v., s.c., and i.m. routes. Control groups received nothing or
empty liposomes (Lip) through the respective routes. Ten days after the last immunization, the mice were challenged intravenously with 2.5  107
promastigotes of L. donovani. The parasite loads in the livers and spleens of i.p. (A and B), i.v. (C and D), s.c. (E and F), and i.m. (G and H) immunized
animals are expressed in Leishman Donovan units. Data represent mean values 	 standard errors (SE) for five mice per group at the designated time
points and are representative of two independent experiments with similar results. #, P  0.05; *, P  0.01; **, P  0.001 for comparison to control
groups (mice left unimmunized or immunized with empty liposomes by the respective routes).
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reduction in parasite burden were observed in mice immunized
i.p. with LAg in liposomes at 2 (83%) and 4 (90%) months of
infection compared to controls (P  0.001) and mice immu-
nized with free antigen (P  0.01). These findings strengthen
our previous observation that LAg in liposomes could signifi-
cantly reduce parasite burdens in BALB/c mice (1). Similarly,
the splenic parasite burden was reduced with free antigen
(48% at 2 months compared to controls; P  0.001), and this
change increased further with liposomal LAg immunization
(ranging from 76% at 2 months to 89% at 4 months compared
to controls; P  0.001) (Fig. 1B). Besides the i.p. route, reduc-
tions in parasite burden were also observed when mice were
immunized through the i.v. route (Fig. 1C and D). Although
the levels of reduction were lower, liposomal LAg induced
significant protection in both the liver (77% and 83% at 2 and
4 months, respectively) and spleen (64% and 83% at 2 and 4
months, respectively) compared to controls (P  0.001). Inter-
estingly, immunization by the s.c. or i.m. route with either free
or liposomal LAg did not result in any reduction in parasite
growth in the liver or spleen (Fig. 1E to H). Mice immunized
through the s.c. or i.m. route developed progressive visceral
infection, as seen in controls.
Immunization through i.p. and i.v. routes induces positive
humoral and DTH responses. To investigate whether protec-
tion in immunized mice correlated with a specific pattern of
immunoglobulin production, mouse sera were assayed for
LAg-specific IgG as well as IgG1 and IgG2a isotypes, conve-
nient surrogate markers of Th1 and Th2 CD4 T-cell differ-
entiation (10) (Fig. 2A). After immunization, sera from differ-
ent groups of mice were examined at various dilutions (1/100,
1/1,000, 1/10,000, and 1/100,000), and the 1/1,000 dilution was
found to be nonsaturating (data not shown). Mice immunized
with LAg in liposomes via the i.p. and i.v. routes induced
significantly higher levels of IgG, IgG1, and IgG2a than those
in controls (P  0.001). DTH, an index of cell-mediated im-
munity, was evaluated in vaccinated mice to determine the
correlation with the observed protection in the different vac-
cination groups. Mice immunized with free LAg as well as LAg
in liposomes through the i.p. and i.v. routes induced significant
levels of DTH, which gradually increased after 2 and 4 months
of infection in comparison to the control groups (P  0.001)
(Fig. 2B and C). The level of DTH induced by LAg in lipo-
somes was significantly higher than that induced by free LAg
(P  0.001). Mice immunized via the s.c. and i.m. routes did
not exhibit any significant level of DTH, with values compara-
ble to those for controls (Fig. 2D and E).
Production of nitrite in protected i.p. and i.v. immunized
mice. NO is a critical macrophage-derived effector molecule
for the control of Leishmania infections (35). To determine
whether protective and nonprotective routes could induce NO
production, the level of nitrite was estimated in the antigen-
stimulated culture supernatants of splenocytes isolated from
mice in different vaccinated groups after 4 months of infection.
Significant nitrite production was observed in i.p. and i.v. im-
munized mice (P  0.01 compared to controls), whereas in s.c.
and i.m. immunized mice the generation of nitrite was inhib-
ited (Fig. 2F). These data reflect the activated state of splenic
macrophages specific to leishmanial antigen in i.p. immunized
animals, whereas in s.c. immunized animals the macrophages
failed to be activated.
Production of antigen-specific TGF- following vaccination
by the nonprotective s.c. route. To investigate the immuno-
modulatory responses associated with different routes, LAg-
specific recall cytokine responses were measured in splenocyte
cultures of mice vaccinated by the protective i.p. and nonpro-
tective s.c. routes. Table 1 shows that following liposomal LAg
vaccination, splenocytes from i.p. immunized mice produced
significant amounts of IFN-, IL-12, and IL-4 in comparison to
controls as well as s.c. immunized mice (P  0.001). The level
of IFN- was significantly higher in i.p. immunized mice, with
a ratio of IFN- to IL-4 of 2.62 	 0.37, showing a skewing
toward a Th1 response. A nonsignificant increase in the level
of IL-10 was detected in spleen cell supernatants derived from
s.c. vaccinated mice compared with controls. The level of
TNF- remained low in both i.p. and s.c. immunized mice. In
contrast, the level of TGF- was elevated eightfold in s.c.
immunized mice compared to controls and i.p. immunized
mice (P  0.001), indicating a preferential increase in antigen-
specific TGF- production in response to the nonprotective
s.c. route. Progressive disease with L. donovani infection after
4 months showed high levels of IL-4 and IL-10, with reduced
levels of the Th1 cytokines IFN- and IL-12, as also observed
earlier in control animals (7, 19). In addition, control animals
demonstrated high levels of TGF- with a lower level of
TNF-. s.c. immunized animals exhibited similar cytokine pro-
files to those of controls. In contrast, IFN-, IL-12, and TNF-
levels were elevated in i.p. immunized mice, whereas IL-4,
IL-10, and TGF- levels were decreased significantly com-
pared to those in controls as well as s.c. immunized animals
following challenge infection (P  0.001).
Differential macrophage stimulatory activity in spleen cell
supernatants from animals immunized by different routes and
TGF--dependent inhibitory activity of supernatants from the
nonprotective s.c. route. Because cytokine-activated macro-
phages are thought to play a role in the immune effector
mechanism of resistance in vaccine models, the induction of
macrophage-activating cytokines for intracellular parasite kill-
ing upon vaccination by different routes was examined. Super-
natants derived from antigen-stimulated spleen cells from i.p.
immunized animals activated macrophages to kill parasites in
vitro compared to controls (P  0.001) (Fig. 3A). In contrast,
spleen supernatants from mice immunized by the nonprotec-
tive s.c. route were not potent macrophage activators. IL-4,
IL-10, and TGF- can prevent macrophage activation. To test
the possible effect of these cytokines in supernatants from
nonprotected mice, we added antibodies to these cytokines
during the cytotoxicity assay. Neither anti-IL-4 nor anti-IL-10
antibodies significantly increased the level of macrophage ac-
tivity observed with s.c. supernatants above that seen with
control antibodies (Fig. 3B). Interestingly, s.c. supernatants in
the presence of anti-TGF- antibody showed a dramatic in-
crease in macrophage-activating capacity, and the killing activ-
ity was further increased in the presence of IFN- (P  0.001)
compared to the control level. These data suggest a potential
role of TGF- in the suppression of killing activity via the
nonprotective s.c. route. Since TGF- can inhibit macro-
phage activation, we then tested the effect of the addition of
rTGF- to i.p. supernatants on macrophage activation of
leishmanicidal activity. Inhibition with i.p. supernatants was
achieved at levels of rTGF- of 
1 ng/ml (Fig. 3C), indi-
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FIG. 2. LAg-specific immune responses in mice immunized via four different routes. (A) Serum samples were collected from liposomal LAg-immunized
mice and assayed for LAg-specific IgG, IgG1, and IgG2a levels by ELISA. Data are presented as the absorbance at 450 nm and are means	 SE for five mice
per group in duplicate wells. Data are representative of two independent experiments with similar results. (B to E) Mice were immunized and infected with L.
donovani. DTH responses were measured in i.p. (B), i.v. (C), s.c. (D), and i.m. (E) immunized animals. Results are shown as means	 SE for five mice per group
at the designated time points and are representative of two independent experiments with similar results. (F) Four months after infection, splenocytes derived
from different vaccinated groups were stimulated with LAg (10 g/ml) for 72 h, and the level of nitrite in the culture supernatants was assessed. Results are
means	 SE for five mice per group done in duplicate and are representative of two independent experiments with similar results. *, P 0.01; **, P 0.001
for comparison to control groups (mice left unimmunized or immunized with empty liposomes by the respective routes).
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cating that TGF- can abolish macrophage activity in this
system.
Neutralization of TGF- during vaccination induces protec-
tion, whereas the addition of TGF- causes a failure of pro-
tection. To more directly assess the role of TGF- in the
unprotected s.c. immunized mice, the animals received neu-
tralizing anti-TGF- antibody together with liposomal LAg
vaccination. The neutralization of TGF- was confirmed by the
lower TGF- levels in the sera of animals receiving the vaccine
with anti-TGF- antibody than in those of animals receiving
the vaccine with control antibody (data not shown). We found
that after 4 months of infection, animals covaccinated with
anti-TGF- antibody through the s.c. route showed an 80%
reduction in liver parasite load (Fig. 4A) and a 78% reduction
in spleen parasite load (Fig. 4B) compared to controls (P 
0.001). Since anti-TGF- antibody was administered much
prior to infection challenge, the effect of TGF- neutralization
was at the vaccination stage, not on the infection itself. These
results therefore confirm that augmented TGF- production
during vaccination via the s.c. route is responsible for the
failure of induction of protective immunity. Additionally, to
determine whether TGF- could alter the resistance against
leishmanial infection, mice were injected with liposomal LAg
along with rTGF- during protective i.p. vaccination. rTGF-
treatment led to increases in parasite burden in both the liver
and spleen after 4 months of challenge infection, comparable
to the case in controls (Fig. 4C and D). Thus, a role of TGF-
in the failure of protection in leishmaniasis was established.
DISCUSSION
In this study, we evaluated the protective efficacy of LAg in
liposomes administered through different routes and com-
pared the immune responses for protection against L. dono-
vani in a BALB/c mouse model. Previously, we reported that
positively charged liposomes enhanced the immunogenicity of
the associated LAg and induced significant levels of protection
when injected i.p. (1). Here we demonstrated that the route of
vaccination influenced the development of immune responses
for either protection or failure of protection against L. dono-
vani: i.p. and i.v. routes were protective, whereas s.c. and i.m.
routes failed to induce protection. Moreover, experiments per-
formed to understand the immune mechanism revealed that
the high prechallenge level of TGF- production did predict
the failure of liposomal LAg vaccination via the s.c. route after
challenge infection.
Examination of immune responses of vaccinated mice dem-
onstrated that protected animals immunized via the i.p. as well
as i.v. route stimulated the production of IgG2a and elicited
profound DTH responses. This result extends our earlier re-
port that protection in mice vaccinated via the i.p. route was
associated with increased DTH responses and enhanced IgG2a
production (1). Analysis of cytokines from spleen cells re-
vealed that animals vaccinated via the protective i.p. route
produced both prechallenge IFN- and IL-4, with a skewing
toward a Th1 response essential for resistance against L. do-
novani (7, 19, 20). Interestingly, unprotected mice induced
elevated levels of TGF-, with downregulation of both Th1
and Th2 cytokines, before infection. It has been reported that
TNF- acts as a triggering signal for NO production (13), and
NO has a central role in parasite clearance (25). The produc-
tion of NO and TNF- in splenocyte culture supernatants from
i.p. immunized mice as well as the failure of NO generation in
s.c. immunized mice confirms that an NO-mediated macro-
phage effector mechanism is critical in the control of L. dono-
vani replication in the mouse (25). Splenocyte supernatants
from unprotected mice lacked macrophage activation in vitro,
and anti-IL-4 and anti-IL-10 antibodies did not substantially
increase macrophage leishmanicidal activity. The inhibitory
activity of s.c. supernatants was neutralized by anti-TGF-
antibody, and the addition of rTGF- to i.p. supernatants
inhibited macrophage activation in vitro. The observations that
neutralization of TGF-, elicited by the nonprotective s.c.
route, by anti-TGF- antibody in vivo induced protection in
both the liver and spleen and that rTGF- treatment with
liposomal LAg vaccination by the protective i.p. route abro-
gated the protection are powerful evidence in support of the
view that TGF- plays a major role in inhibiting the develop-
ment of a protective immune effector mechanism against L.
donovani infection.
TABLE 1. Cytokine levels in spleen cell supernatants from mice immunized via different routes
Vaccination group
Cytokine concn (pg/ml)a
IFN- IL-12 IL-4 IL-10 TNF- TGF-
Groups after immunization
Control 21 	 3 22 	 3 15 	 2 16 	 4 11 	 1 93 	 16
Liposomes i.p. 22 	 3 24 	 3 14 	 2 20 	 1 13 	 5 105 	 6
Liposomes s.c. 23 	 4 22 	 2 13 	 3 18 	 4 12 	 2 102 	 8
Liposomal LAg i.p. 120 	 7b 95 	 8b 48 	 5b 22 	 4 19 	 5 114 	 6
Liposomal LAg s.c. 28 	 3 25 	 3 21 	 3 31 	 3 14 	 4 924 	 87b
Groups 4 mo after
infection
Control 31 	 2 27 	 4 93 	 8 230 	 21 24 	 4 1,652 	 81
Liposomes i.p. 37 	 2 28 	 3 87 	 8 228 	 14 24 	 3 1,624 	 113
Liposomes s.c. 32 	 4 30 	 4 86 	 6 220 	 11 29 	 4 1,540 	 125
Liposomal LAg i.p. 274 	 18b 168 	 10b 37 	 4b 33 	 4b 126 	 9b 113 	 9b
Liposomal LAg s.c. 38 	 3 32 	 3 97 	 7 228 	 8 28 	 4 1,680 	 77
a Data are for five mice and are expressed as means 	 standard errors. Data are representative of two independent experiments with similar results.
b P  0.001 in comparison to control groups.
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FIG. 3. Effects of splenocyte supernatants (SN) of immunized mice on intracellular parasite growth in peritoneal macrophages in the absence
(A) and presence of anticytokine antibodies (Ab) (B) or TGF- (C). Peritoneal macrophages harvested from naive mice were pretreated for 12
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The critical dependence on the route of immunization in
obtaining protective immunity using protein antigens has been
evaluated for L. major infection. In these studies, i.v. and, to a
lesser extent, i.p. immunization was protective, and the s.c. and
i.m. routes were ineffective (17). In the present study, we ob-
served that despite the different pattern of disease caused by
the species L. donovani, which is phylogenetically distant from
L. major (20), i.p. and i.v. routes were protective and s.c. and
i.m. routes were nonprotective against VL. To the best of our
knowledge, however, none of the previous studies reported the
priming of strong TGF- production following vaccination by
the nonprotective routes. TGF- has multiple suppressive ac-
tions on T cells, B cells, and macrophages (28) and can inhibit
both Th1 and Th2 differentiation (15). TGF- has been found
to inhibit the DTH response (21) and to suppress macrophage
activation and NO production (8, 34). It has been found that
the production of TGF- during Leishmania infection corre-
lates with in vivo susceptibility (4). Moreover, a role of TGF-
has been observed in the failure of protective immunity via
specific routes against Schistosoma mansoni (38). Induction of
oral tolerance and prevention of Th1 cell-mediated experimen-
tal autoimmune encephalomyelitis by feeding of self-antigens
to 18 h with supernatants from s.c. immunized mice either alone or in the presence of 10 g/ml of each of the anticytokine antibodies and
appropriate isotype-matched control antibodies. IFN- at 10 ng/ml was used as a positive control. Again, macrophages were pretreated with
supernatants from i.p. immunized mice alone or with various concentrations of TGF- ranging from 0.5 to 100 ng/ml. After 3 h of infection,
unphagocytosed parasites were removed by washing with PBS and cultured in the same medium with supernatants, IFN-, antibodies, or TGF-,
using similar concentrations. Seventy-two hours later, the number of intracellular amastigotes was determined. Results are means 	 SE for five
experiments done in triplicate. **, P  0.001 for comparison to control groups.
FIG. 4. In vivo effects of anti-TGF- antibody (Ab) and TGF- during vaccination via nonprotective s.c. and protective i.p. routes. Mice were
vaccinated three times with liposomal LAg with 100 g of anti-TGF- or control antibody at 2-week intervals through the s.c. route. Control groups
received nothing or anti-TGF- antibody. Ten days after the last immunization, the mice were challenged intravenously with 2.5  107
promastigotes of L. donovani. After 4 months, parasite loads in the liver (A) and spleen (B) were measured and expressed in Leishman Donovan
units. Mice were vaccinated three times with liposomal LAg, alone or in combination with 5 g TGF-, at 2-week intervals through the i.p. route
and infected with L. donovani. After 4 months of challenge infection, parasite loads in the liver (C) and spleen (D) were measured and expressed
in Leishman Donovan units. Data represent mean values 	 SE for five mice per group. **, P  0.001 for comparison to control groups.
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were associated with the generation of TGF--secreting T cells
(9). These T cells, producing large amounts of TGF- and
various amounts of IL-4 and IL-10, have been identified as
distinct from Th2 cells and named Th3 cells (9, 23). Th3 cells
primarily secrete TGF- and have suppressive properties for T
and other immune cells (36). Characterization of TGF--se-
creting CD4 clones from animals fed myelin basic protein in
experimental autoimmune encephalomyelitis revealed a clone
which was TGF-high IL-4low IL-10low. These TGF-high clones
produced no IFN- or IL-2 (9). In the present study, we found
a similar cytokine profile after vaccination via the nonprotec-
tive route, suggesting that Th3 cells could be the source of
TGF- during vaccination.
The reason for the production of TGF--secreting Th3 cells
by the s.c. route or, conversely, the suppression of TGF- by
the i.p. route is not clear at present. Th3 cells are inducible
Treg cells, which develop in the periphery from conventional
CD4 T cells after exposure to signals such as regulatory
cytokines, immunosuppressive drugs, or antigen-presenting
cells (APCs) conditioned by microbial products. Furthermore,
some pathogens target sites in which TGF- is highly pro-
duced, such as the gastrointestinal tract, the skin, and the eye
(5). The i.p. and s.c. routes of immunization used herein ex-
pose the liposomal antigen to different sets of APCs for the
primary encounter. When the i.p. route was used, peritoneal
macrophages would be the major population of APCs avail-
able, whereas DCs would be the main APCs during s.c. immu-
nization. It has been found that induction of the immune
response by liposomal delivery of antigen is macrophage de-
pendent, and DCs are considered to be less efficient in phago-
cytosis than cells of the macrophage lineage (37). This may be
enable T cells from i.p. immunized mice to generate a protec-
tive response. Conversely, in models of oral tolerance, it has
been found that DCs, the most potent APCs in activating
resting T cells, possibly present antigens for Th3-cell differen-
tiation under the influence of the gut cytokine milieu (36).
Thus, it is interesting to speculate that APCs at the site of
vaccination may influence the cytokine profile of the subse-
quent immune response. To promote protective immune re-
sponses, it would be better to select a site of vaccination where
Treg cells were not overrepresented, as vaccination itself can
generate its own set of Treg cells. The skin contains the highest
percentage of natural Treg cells in the body. Moreover, con-
ventional T cells converted into Treg cells in the periphery
under subimmunogenic conditions can subsequently be ex-
panded by the delivery of antigen under immunogenic condi-
tions (5, 6). Thus, the optimal conditions of vaccination should
include a site that can minimize Treg priming or activation.
In conclusion, we demonstrated that vaccination of BALB/c
mice with free LAg or LAg entrapped in liposomes through i.p.
and i.v. routes induced protective immunity against infection
with L. donovani, whereas s.c. and i.m. routes failed to induce
protection with the same antigens. The failure of protection by
the s.c. route was manifested by enhanced prechallenge TGF-
production following vaccination. These results clearly illus-
trate the fact that in designing an effective vaccine against L.
donovani or other intracellular pathogens, it is critical to con-
sider the route of immunization that not only leads to produc-
tion of cytokines directly stimulating protective mechanisms
but also can inhibit the production of suppressive cytokines,
such as TGF-.
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